<DOC>
	<DOCNO>NCT00319852</DOCNO>
	<brief_summary>The present clinical study assess immunogenicity reactogenicity Sanofi Pasteur 's DTaP-IPV combine vaccine three-dose primary vaccination 2 , 4 6 month age compare commercially available vaccine order meet requirement registration product South Korea . Primary objective To demonstrate non-inferiority term seroprotection rate ( Diphtheria , Tetanus , Polio type 1 , 2 3 ) seroconversion/vaccine response rate Pertussis antigens ( PT , FHA ) Sanofi Pasteur 's DTaP-IPV combine vaccine versus commercially available Biken 's DTaP ( CJ purify PDT vaccine ™ ) Aventis Pasteur 's IPV ( IMOVAX POLIO ) monovalent vaccine , one month three-dose primary vaccination . Secondary objective 1 . Immunogenicity : To assess non-inferiority term seroprotection rate ( Diphtheria , Tetanus , Polio type 1 , 2 3 ) seroconversion / vaccine response rate Pertussis antigens ( PT , FHA ) Sanofi Pasteur 's DTaP-IPV combine vaccine versus historical reference ( Study E2I03294 - France ) . To assess describe immunogenicity study vaccine group . 2 . Safety : To assess describe safety study vaccine dose .</brief_summary>
	<brief_title>Immunogenicity Safety Tetraxim Versus Local DTP + IPV</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 56 70 day inclusive day inclusion Born full term pregnancy ( &gt; 37 week ) birth weight ≥ 2.5 kg Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure Participation another clinical trial 4 week precede ( first ) trial vaccination Planned participation another clinical trial present trial period . Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy . Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive past plan administration trial ( include immunoglobulin ) . Any vaccination 3 week precede first trial vaccination . History diphtheria , tetanus , pertussis , poliomyelitis infection ( confirm either clinically , serologically microbiologically ) . Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis disease trial vaccine another vaccine . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History major neurological disease seizure . Febrile illness ( rectal temperature ≥ 38.0°C axillary temperature ≥ 37.4°C ) day inclusion . Known family history congenital genetic immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>56 Days</minimum_age>
	<maximum_age>70 Days</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diphteria ;</keyword>
	<keyword>Tetanus ;</keyword>
	<keyword>Pertussis ;</keyword>
	<keyword>Poliomyelitis ;</keyword>
	<keyword>acellular</keyword>
</DOC>